370 related articles for article (PubMed ID: 28589321)
1. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
[TBL] [Abstract][Full Text] [Related]
2. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
3. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
[TBL] [Abstract][Full Text] [Related]
4. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.
Lee H; Park HY; Jeon K; Jeong BH; Hwang JW; Lee J; Cha HS; Koh EM; Kang ES; Koh WJ
PLoS One; 2015; 10(3):e0119260. PubMed ID: 25746854
[TBL] [Abstract][Full Text] [Related]
5. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
[TBL] [Abstract][Full Text] [Related]
6. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.
Pyo J; Cho SK; Kim D; Sung YK
Korean J Intern Med; 2018 Nov; 33(6):1241-1251. PubMed ID: 29277097
[TBL] [Abstract][Full Text] [Related]
7. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
[TBL] [Abstract][Full Text] [Related]
8. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
[TBL] [Abstract][Full Text] [Related]
10. How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis?
Busquets-Pérez N; Ponce A; Ortiz-Santamaria V; de Agustín de Oro J; Hernández-Rico YL; Vidal I; Alfonso C; Argemí S; Muñoz B; Quispe F; Díaz AC; Campos S; Hernández TM; Torres M; Surís X
Reumatol Clin; 2017; 13(5):282-286. PubMed ID: 27394672
[TBL] [Abstract][Full Text] [Related]
11. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
[TBL] [Abstract][Full Text] [Related]
12. A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy.
Xie X; Chen JW; Li F; Tian J; Gao JS; Zhang D
Clin Exp Med; 2011 Sep; 11(3):155-61. PubMed ID: 21161670
[TBL] [Abstract][Full Text] [Related]
13. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
[TBL] [Abstract][Full Text] [Related]
15. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
Sellam J; Hamdi H; Roy C; Baron G; Lemann M; Puéchal X; Breban M; Berenbaum F; Humbert M; Weldingh K; Salmon D; Ravaud P; Emilie D; Mariette X;
Ann Rheum Dis; 2007 Dec; 66(12):1610-5. PubMed ID: 17456528
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
[TBL] [Abstract][Full Text] [Related]
18. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
19. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
[TBL] [Abstract][Full Text] [Related]
20. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
Ringrose JS; Sanche SE; Taylor-Gjevre RM
Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]